Invesco
MRSN

Invesco’s Mersana Therapeutics MRSN Stock Holding History

Invesco’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,595
Closed -$39.5K – 3829
2025
Q1 		$39.5K Buy
4,595
+2,400
+109% +$37K ﹤0.01% 3716
2024
Q4 		$78.5K Sell
2,195
-24
-1% -$1.24K ﹤0.01% 3652
2024
Q3 		$105K Buy
2,219
+417
+23% +$18.4K ﹤0.01% 3614
2024
Q2 		$90.6K Sell
1,802
-11,174
-86% -$808K ﹤0.01% 3764
2024
Q1 		$1.45M Buy
12,976
+11,027
+566% +$1.1M ﹤0.01% 2820
2023
Q4 		$113K Sell
1,949
-652
-25% -$26.2K ﹤0.01% 3669
2023
Q3 		$82.6K Buy
2,601
+1,056
+68% +$50.2K ﹤0.01% 3748
2023
Q2 		$127K Buy
1,545
+233
+18% +$34.1K ﹤0.01% 3687
2023
Q1 		$135K Sell
1,312
-19
-1% -$2.67K ﹤0.01% 3682
2022
Q4 		$195K Sell
1,331
-21,120
-94% -$3.57M ﹤0.01% 3687
2022
Q3 		$3.79M Buy
22,451
+21,283
+1,822% +$3.46M ﹤0.01% 2360
2022
Q2 		$135K Sell
1,168
-35
-3% -$3.29K ﹤0.01% 3825
2022
Q1 		$120K Buy
1,203
+14
+1% +$1.64K ﹤0.01% 3852
2021
Q4 		$185K Sell
1,189
-99
-8% -$19.3K ﹤0.01% 3803
2021
Q3 		$303K Buy
1,288
+206
+19% +$60.2K ﹤0.01% 3647
2021
Q2 		$368K Sell
1,082
-15,405
-93% -$5.83M ﹤0.01% 3550
2021
Q1 		$6.67M Sell
16,487
-36,737
-69% -$17.8M ﹤0.01% 2213
2020
Q4 		$35.4M Buy
53,224
+8,527
+19% +$4.74M 0.01% 1156
2020
Q3 		$20.8M Buy
44,697
+5,385
+14% +$2.72M 0.01% 1285
2020
Q2 		$23M Buy
+39,312
New +$13.4M 0.01% 1225

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco's MRSN Position: Q2 2025 in Review

Invesco sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 4,595 shares — an estimated $39.5K sold.

Invesco first reported a position in MRSN in Q2 2020 and held it in 20 quarters. The position peaked at $35.4M in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Invesco reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 4,595 Mersana Therapeutics shares in Q2 2025, an estimated $39.5K.
  • Invesco first reported a position in Mersana Therapeutics in Q2 2020 and held it in 20 quarters.
  • Invesco's Mersana Therapeutics position peaked at $35.4M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.